Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ViroPharma down on pleconaril data

VPHM was down $48.50 (68 percent) to $23.25 on Tuesday after missing the primary end points in three Phase III trials of pleconaril to treat two

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE